西拉多巴

**西拉多巴**
臨床資料
給藥途徑	Oral
ATC碼	未分配;
法律規範狀態
法律規範	Uncontrolled;
識別資訊
	IUPAC命名法 2-{4-[(2S)-2-(3,4-dimethoxyphenyl)-2-hydroxyethyl]piperazin-1-yl}cyclohepta-2,4,6-trien-1-one; ;
CAS號	80109-27-9
PubChem CID	133371;
ChemSpider	117659;
UNII	D09L486R3J;
ChEMBL	ChEMBL2110793;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID101024642 ;
化學資訊
化學式	C21H26N2O4
摩爾質量	370.45 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES O=C3/C=C\C=C/C=C3/N2CCN(C[C@@H](O)c1ccc(OC)c(OC)c1)CC2;

西拉多巴（英語：Ciladopa，研發代號：AY-27,110）是一種含氮有機化合物，化學式C₂₁H₂₆N₂O₄，化學結構與多巴胺相似，能作為多巴胺激動劑^[1]。曾被研究作為抗帕金森病的藥物，但由於動物實驗中存在癌變風險而停用^[2]^[3]^[4]^[5]。

參考文獻

^ Voith K. The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats. Psychopharmacology. 1985, 85 (4): 405–9. PMID 3927334. S2CID 1573473. doi:10.1007/BF00429654.
^ Koller WC, Fields JZ, Gordon JH, Perlow MJ. Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug. Neuropharmacology. September 1986, 25 (9): 973–9. PMID 3774130. S2CID 19175441. doi:10.1016/0028-3908(86)90190-5.
^ Weiner WJ, Factor SA, Sanchez-Ramos J, Berger J. A double-blind evaluation of ciladopa in Parkinson's disease. Movement Disorders. 1987, 2 (3): 211–7. PMID 3332914. S2CID 31784301. doi:10.1002/mds.870020308.
^ Lieberman A, Gopinathan G, Neophytides A, Pasternack P, Goldstein M. Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa. Neurology. May 1987, 37 (5): 863–5. PMID 3574692. S2CID 25273606. doi:10.1212/wnl.37.5.863.
^ Lang AE. Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine". The Canadian Journal of Neurological Sciences. August 1987, 14 (3 Suppl): 474–82. PMID 3315148. doi:10.1017/s031716710003794x .